Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.

as well as genetic testing and drug monitoring services. Quest reported revenues of $2.62 billion, up 14.6% year on year. This print exceeded analysts’ expectations by 1.8%. Overall, it was a ...